Protara Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Protara Therapeutics

03/11/2023 12:57

* Protara Therapeutics Inc  TARA.OQ  reported a quarterly
adjusted
loss of 87 cents​​ per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of -68 cents.  The mean expectation of four analysts for the
quarter was for a loss of 98 cents per share. Wall Street
expected results to range from $-1.12 to -66 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Protara Therapeutics Inc's reported EPS for the quarter
was a
loss of 87 cents​.
    * The company reported a quarterly loss of $9.86 million.
    * Protara Therapeutics Inc shares had fallen by 27.5% this
quarter and lost 54.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Protara
Therapeutics Inc is $30.00 
This summary was machine generated from LSEG data November 3 at
12:57 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.98          -0.87          Beat
 Jun. 30 2023      -0.87          -1.00          Missed
 Mar. 31 2023      -0.88          -0.80          Beat
 Dec. 31 2022      -0.75          -1.55          Missed